Saturna Capital Corp Has $22.52 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Saturna Capital Corp cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 778,150 shares of the biopharmaceutical company’s stock after selling 23,050 shares during the period. Saturna Capital Corp’s holdings in Pfizer were worth $22,520,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Olistico Wealth LLC acquired a new position in shares of Pfizer during the second quarter worth $25,000. MFA Wealth Advisors LLC acquired a new position in Pfizer during the 2nd quarter worth about $29,000. Quarry LP bought a new stake in shares of Pfizer in the 2nd quarter valued at about $31,000. Financial Connections Group Inc. bought a new position in shares of Pfizer during the second quarter worth about $34,000. Finally, ESL Trust Services LLC acquired a new position in shares of Pfizer in the first quarter worth approximately $37,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

NYSE PFE opened at $26.25 on Wednesday. The company has a market cap of $148.76 billion, a P/E ratio of 35.38, a PEG ratio of 0.83 and a beta of 0.67. The company has a fifty day simple moving average of $28.80 and a 200 day simple moving average of $28.68. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the company earned ($0.17) earnings per share. The business’s revenue was up 31.2% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.40%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Citigroup started coverage on shares of Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target for the company. UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Wells Fargo & Company upped their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Sanford C. Bernstein started coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Insider Activity

In related news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.